Dynasore: Precise Dynamin GTPase Inhibition for Endocytosis Research

Executive Summary: Dynasore (SKU A1605, APExBIO) is a cell-permeable, noncompetitive inhibitor that selectively targets dynamin GTPases with an IC50 of 15 µM, enabling rapid and reversible inhibition of endocytosis across diverse cell types (APExBIO product page). It blocks clathrin-mediated endocytosis and macropinocytosis, as evidenced in Drosophila S2 cells and mammalian systems (Wei et al., 2019). Dynasore is insoluble in water and ethanol but dissolves in DMSO at ≥16.12 mg/mL, requiring careful preparation for experimental reproducibility. Its use extends from fundamental cell biology to applied research in cancer and neurodegenerative disease models. Use of Dynasore has been pivotal in clarifying vesicle trafficking and signal transduction mechanisms in cellular and disease contexts.

Biological Rationale

Dynamins are large GTPase enzymes essential for membrane scission events during endocytosis, vesicle trafficking, and organelle division. These proteins, including dynamin1, dynamin2, and Drp1, hydrolyze GTP to drive conformational changes that pinch off vesicles from the plasma membrane (Wei et al., 2019). Endocytosis underpins critical functions such as nutrient uptake, receptor recycling, synaptic transmission, and signal transduction. Disruptions in dynamin-dependent pathways are linked to diseases including cancer, neurodegeneration, and pathogen entry (Related Article 1).

Mechanism of Action of Dynasore

Dynasore is a small molecule that noncompetitively inhibits the GTPase activity of dynamin1, dynamin2, and Drp1. It blocks the hydrolysis of GTP but does not interfere with GTP binding itself (APExBIO). This selective inhibition prevents the conformational changes required for vesicle fission, resulting in immediate and reversible arrest of clathrin-mediated and dynamin-dependent endocytosis. In cellular assays, Dynasore rapidly suppresses transferrin uptake and synaptic vesicle recycling in a dose-dependent manner (Related Article 2). Notably, Dynasore does not inhibit caveolae-mediated endocytosis or pathways that are independent of dynamin action (Wei et al., 2019).

Evidence & Benchmarks

• Dynasore inhibits dynamin GTPase activity with an IC50 of 15 µM in vitro (APExBIO, product page).
• In Drosophila S2 cells, Dynasore treatment significantly reduces Spiroplasma eriocheiris internalization by blocking clathrin-mediated endocytosis (Wei et al., 2019, DOI).
• Dynasore reversibly inhibits transferrin uptake and synaptic vesicle endocytosis in neuronal and cardiac cell models (APExBIO, link).
• Dynasore does not disrupt cholesterol-dependent caveolae-mediated endocytosis, as confirmed by resistance to methyl-β-cyclodextrin and nystatin interventions (Wei et al., 2019, DOI).
• Dynasore’s inhibition is rapid, reversible, and dose-dependent, allowing for temporal control in live-cell assays (Related Article 1).

This article extends "Dynasore in Context" by providing updated mechanistic details and explicit experimental benchmarks from recent peer-reviewed studies.

Applications, Limits & Misconceptions

Dynasore is widely used to dissect dynamin-dependent endocytosis, vesicle trafficking, and related signaling pathways. Its applications include:

• Analyzing endocytic pathway specificity in basic and translational research.
• Modeling cancer cell uptake and drug resistance mechanisms (Related Article 5).
• Studying synaptic vesicle recycling and neurodegenerative disease mechanisms.
• Elucidating pathogen entry strategies, as demonstrated in S2 cell infection models.

Common Pitfalls or Misconceptions

• Dynasore is not effective against endocytic pathways that are dynamin-independent (e.g., caveolin-mediated or clathrin-independent uptake).
• The compound is insoluble in water and ethanol, requiring dissolution in DMSO at concentrations ≥16.12 mg/mL and proper warming or sonication.
• Dynasore’s effects are reversible; prolonged exposure or repeated dosing does not guarantee sustained inhibition.
• It is unsuitable for in vivo diagnostic or therapeutic applications and is intended solely for research use.
• Cellular toxicity may occur at concentrations significantly above the recommended IC50 or with extended exposure times.

Workflow Integration & Parameters

For experimental use, Dynasore should be dissolved in DMSO (≥16.12 mg/mL), optionally warmed at 37°C or sonicated to ensure complete solubilization. Stock solutions must be stored at -20°C. Working dilutions should be freshly prepared and used promptly to minimize compound degradation. Recommended concentrations depend on cell type and assay, but commonly range from 10–80 µM for acute endocytosis inhibition (APExBIO). Controls should include DMSO vehicle and, where possible, alternative pathway inhibitors for specificity checks. For detailed protocol guidance and scenario-driven application, see this article; here, we provide updated benchmarks and clarify storage/handling.

Conclusion & Outlook

Dynasore has become an essential tool for dissecting dynamin-dependent endocytic and vesicle trafficking pathways. Its rapid, reversible inhibition enables precise temporal analysis in cellular systems. Limitations include solubility constraints and specificity for dynamin-dependent routes. However, when applied with appropriate controls and protocols, Dynasore (from APExBIO) offers reproducible and interpretable results for endocytosis research and disease modeling. Ongoing research is expanding its use into complex disease and pathogen entry models, underscoring the importance of validated, mechanism-specific inhibitors in modern cell biology.